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Abstract
Background:  A very high prevalence (22.3%) of gestational diabetes mellitus (GDM) was recently
reported following our study on a large group of Sardinian women. In order to explain such a high
prevalence we sought to characterise our obstetric population through the analysis of risk factors and their
association with the development of GDM.
Methods: The prevalence of risk factors and their association with the development of GDM were
evaluated in 1103 pregnancies (247 GDM and 856 control women). The association of risk factors with
GDM was calculated according to logistic regression. Sensitivity and specificity of risk assessment strategy
were also calculated.
Results: None of the risk factors evaluated showed an elevated frequency in our population. The high risk
patients were 231 (20.9%). Factors with a stronger association with GDM development were obesity (OR
3.7, 95% CI 2.08–6.8), prior GDM (OR 3.1, 95% CI 1.69–5.69), and family history of Type 2 diabetes (OR
2.6, 95% CI 1.81–3.86). Only patients over 35 years of age were more represented in the GDM group
(38.2% vs 22.6% in the non-GDM cases, P < 0.001). Type 2 diabetes in second-degree relatives was equally
represented in GDM and non-GDM subjects, while prior poor obstetrical outcomes mostly characterized
non-GDM women (17.5% vs 10.6%, P < 0.001). The "average risk" assessment better characterized non-
GDM patients (76.8% vs 57.8%, P < 0.001). The logistic regression analysis confirmed that Type 2 diabetes
in second-degree relatives, prior poor obstetrical outcomes and the "average risk" definition did not
predict the development of GDM.
Conclusion: Such a high prevalence of GDM in our population does not seem to be related to the
abnormal presence of some known risk factors, and appears in contrast with the prevalence of Type 2
diabetes in Sardinia. Further studies are needed to explain the cause such a high prevalence of GDM in
Sardinia. The "average risk" definition is not adequate to predict GDM in our population.
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Background
Gestational diabetes mellitus (GDM) is defined as a "car-
bohydrate intolerance of variable severity with onset or
first recognition during pregnancy"[1].
The prevalence of GDM may range from 1 to 14% of all
pregnancies, depending on the population studied, the
diagnostic test employed, its glycemic cut-off and the rec-
ommendations applied, and it mirrors that of Type 2 dia-
betes mellitus [2-4]. Important risk factors include higher
maternal age, marked obesity (BMI ≥ 30 kg/m2), personal
history of GDM, ethnicity and family history of Type 2
diabetes in first-degree relatives [5]. The prevalence of
GDM increases with age, becoming more frequent over
the age of 30 [6,7]. However, a consistent proportion of
women with gestational diabetes are under 30 [7-9]. For
these reasons both the American Diabetes Association
(ADA) and the American College of Obstetrics and
Gynaecologist (ACOG) now consider age ≥ 25 years as a
risk factor. As for Type 2 diabetes, obesity is also a major
risk factor for GDM, and a Body Mass Index (BMI) > 30
kg/m2 classifies a pregnant woman as high risk for GDM
[10]. Overweight (BMI between 25 and 30 kg/m2) is also
reported to be associated with GDM [9] and for a woman
to be defined as low risk for GDM by the ADA and the
ACOG [10,11] her weight must be considered normal
before pregnancy. Ethnicity influences both the preva-
lence of GDM and the age it occurs [6,12,13] and Type 2
diabetes mellitus [14]. Reported high risk populations are
Hispanic, African, Native American, South or East Asian,
or those with Pacific Island ancestry. Women with GDM
who have a first degree relative with Type 2 diabetes but
not Type 1 diabetes have been reported to have an
increased risk of GDM, confirming that GDM and Type 2
share the same genetic background [9,15-17]. However,
the use of traditional risk factors to identify GDM excludes
approximately half the women with GDM [7]. Further-
more, specific risk factors and their degree of influence on
GDM prevalence in a specific population are difficult to
quantify, and different studies on various populations
have shown differing results [6,18]. It is therefore pro-
posed that the definition of high and low risk for GDM of
each ethnic group be based on the prevalence of Type 2
diabetes [11]. The use of historic risk factors is now recom-
mended to identify women who should be submitted to
diagnostics test for GDM detection. The ADA recom-
mends risk assessment for GDM at the first prenatal visit
and the definition of high, average and low risk be made
on the basis of presence/absence of risk factors. Women
are classified as having a low risk of GDM if they meet all
of the following characteristics: age < 25 years, normal
weight before pregnancy, belonging to an ethnic group
with a low prevalence of GDM, no known diabetes in first
degree relatives, no history of poor obstetric outcome.
High risk must be assessed if any of the following risk fac-
tors are present: marked obesity (BMI ≥ 30 kg/m2), per-
sonal history of GDM, family history of Type 2 diabetes in
first-degree relatives. Patients with intermediate character-
istics have to be defined as at average risk. Screening with
an Oral Glucose Challenge Test (OGCT) followed by an
Oral Glucose Tolerance Test (OGTT) on that subset of
women exceeding the glucose threshold on the OGCT, or
a direct OGTT is recommended as soon as feasible in high
risk patients. Women of average risk should be tested at
24–28 weeks of gestation, and low risk status requires non
glucose testing.
The island of Sardinia, Italy, has an average yearly stand-
ardized incidence rate of 33.4 per 100000 (95% C.I.
30.60, 35.88) of Type 1 diabetes, which is the second
highest in the world after Finland [19-22], and a high
prevalence of other autoimmune diseases Type 1 diabetes
related, such as Multiple Sclerosis, Celiac Disease,
Autoimmune Thyroid Disease and others [23-26]. For
these reasons, Sardinia represents an ideal observatory for
investigating genetic and immunological factors. Never-
theless, the prevalence of Type 2 diabetes (3,75% in males
e 2,74% in females) in the Sardinian population is similar
to that of other, non high-risk populations [27]. We
recently reported a very high prevalence (22.3%) of GDM
in a large group of Sardinian women [28] compared to
that reported in other Italian regions, where it ranges from
2.3 to 10% [29-33]. This high prevalence is only partially
explainable by our extended screening procedure, and
seems to be in contrast with the reported prevalence of
Type 2 diabetes in Sardinia and with the average fre-
quency of GDM in a country known for its high occur-
rence of Type 1 diabetes, such as Finland [34].
In order to better explain the reasons for such a high prev-
alence we sought to characterize our obstetric population
through the analysis of risk factors, their prevalence and
their association with the development of GDM.
Methods
Screening and diagnosis of GDM were performed accord-
ing to the American Diabetes Association (ADA) crite-
ria[10] in 1103 pregnant volunteers (247 GDM and 856
control women), consecutively referred to our Obstetric
Diagnostic Centre, as previously reported [28]. All sub-
jects were white and of Sardinian descent. None of the
participants had Type 2 diabetes outside the index preg-
nancy, any significant medical problems, nor were they
taking any medications known to affect glucose metabo-
lism. The purpose and nature of the study were explained
to all subjects, and their consent was obtained before par-
ticipation. The local Institutional Review Board approved
the study.Reproductive Biology and Endocrinology 2008, 6:26 http://www.rbej.com/content/6/1/26
Page 3 of 7
(page number not for citation purposes)
To avoid undiagnosed cases of GDM, an Oral Glucose
Challenge Test (OGCT) was performed at three different
gestational ages (16–18 weeks, 24–26 weeks, and 30–32
weeks), and 130 mg/dl was chosen as the glycemic thresh-
old for the Oral Glucose Tolerance Test (OGTT). The ADA
recommendations (Carpenter and Coustan criteria: two
or more values meeting or exceeding the following: fast-
ing: 95 mg/dl, 1 h: 180 mg/dl, 2 h: 155 mg/dl, 3 h: 140
mg/dl) were used to diagnose GDM.
The risk of GDM was assessed according to the Fourth
International Workshop on GDM [1]. Briefly, women
were classified as having a low risk of GDM if they met all
the following characteristics: age ≤ 25 years, normal
weight before pregnancy, belonging to an ethnic group
with a low prevalence of GDM, no known diabetes in first
degree relatives, no history of poor obstetric outcome.
High risk was assessed if even one of the following risk
factors was present: marked obesity (BMI ≥ 30 kg/m2),
personal history of GDM, family history of Type 2 diabe-
tes in first-degree relatives. Patients with intermediate
characteristics, such as age ≥ 25 years, Type 2 diabetes in
second degree relatives, overweight (BMI: 25–30 kg/m2),
prior poor obstetrical outcomes usually associated with
GDM (macrosomia, polydramnios, repeated abortions,
foetal death) were classified as having an "average risk".
Statistical analysis
Statistical differences between GDM and non-GDM
patients were performed with a Student t-test for continu-
ous variables and with a Chi-Square test for others nomi-
nal variables. To evaluate association with GDM, risk
factors were introduced in a model of logistic regression,
using a selection procedure by steps. Classes of risk (high,
average, low risk) were analysed with a 2 × 2 contingency
table, to validate risk assessment strategy by sensitivity
and specificity evaluation. All analysis was performed
using SPSS v 12.0 software. For all analysis, P < 0.05 was
considered to be statistically significant.
Results
The risk assessment for GDM and risk factors distribution
are shown in Table 1. In the overall population, 6.4% (N
= 71) were classified as "low risk", 72.6% (N = 801) as
"average risk", and 20.9% (N = 231) as "high risk". The
main factor responsible for the low prevalence of "low
risk" patients was that the majority of patients were ≥ 25
years of age. Factors contributing to a "high risk" classifi-
cation (verified in 231 women) included Type 2 diabetes
in a 1st degree relative (67%), BMI ≥ 30 (23.3%) and his-
tory of prior GDM (22%). Multiple risk factors were
present in 37.4% of average risk patients and in 11.6% of
high-risk patients.
The comparison between patients' characteristics in GDM
and non-GDM subjects is shown in Table 2. Women diag-
nosed with GDM had a higher probability of having a first
degree relative with Type 2 Diabetes (26.4 vs 10.7%, P <
0.001), whereas the presence of Type 2 diabetes in second
degree relatives was equally represented in GDM and non-
GDM patients. When divided into age groups, only
patients over 35 had a higher likelihood of becoming ges-
tational diabetics, i.e., 38.4% of the GDM cases were older
than 35 (vs 22.5% of the non-GDM cases, P < 0.01), while
the age group 25–35 was represented equally in GDM and
non-GDM group.
A history of prior GDM was also associated with a higher
risk of developing GDM in the index pregnancy (10.9% of
the GDM cases had a personal history of prior GDM vs
2.8% in non-GDM women, P < 0.001). In contrast, prior
poor obstetrical outcomes were mostly present in non-
GDM patients (17.5% vs 10.6%, respectively, P < 0.001).
However, the risk assessment differentiated GDM from
non-GDM patients only for the high-risk definition, sig-
nificantly more frequent in women subsequently diag-
nosed with GDM (39.8% vs 15%, P > 0.001), whereas
non-GDM patients belonged more frequently to the aver-
age risk category (76.8% vs 57.8%, P < 0.001, Power test:
Table 1: Risk factor distribution in the overall population and in the two classes of risk
Overall
population
(N = 1103)
%
Average Risk
72.6% (N = 801)
%
High Risk
20.9% (N = 231)
%
Age ≥ 25 y 89.3 94. 6
T2DM in 2nd-degree relative(s) 18.5 25.4
Overweight (25 < BMI < 30) 14.5 19.9
T2DM in 1st-degree relative(s) 14.2 ----- 67
Prior poor obstetrical outcomes 12.1 16.7
Obesity (BMI ≥ 30 kg/m2) 4.9 ----- 23.3
Prior GDM 4.6 ----- 22
One risk factor 62.2 88.3
More than one risk factor 37.4 11.6Reproductive Biology and Endocrinology 2008, 6:26 http://www.rbej.com/content/6/1/26
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0.80). The low risk assessment better characterized the
subjects who never developed GDM (7.7% vs 2.0%, P <
0.01).
These results were substantially confirmed by the logistic
regression analysis (Table 3): obesity, strong family his-
tory, prior GDM and age were significantly (P < 0.001)
associated with GDM, but not prior poor obstetrical out-
comes and presence of Type 2 diabetes in second degree
relatives, which characterized the definition of average
risk. Similarly, when analysed in a contingency table
(Table 4), only the high-risk definition was significantly
associated with GDM development (Odd Ratio: 3.6, 95%
CI: 2.6–4.9), whereas the average risk definition was pro-
tective (OR: 0.4, 95% CI: 0.09–0.6), as was the low risk
designation (OR: 0.2, 95% CI: 0.3–0.5). Sensitivity, spe-
cificity, positive and negative predictive values for all three
risk categories are reported in Table 4. The low risk defini-
tion showed a sensitivity of 2%, and specificity of 92%,
whereas the high risk definition showed a specificity of
84.5%, and a sensitivity of 39.8%.
Discussion
This study was performed in order to verify whether some
characteristics of our obstetric population could explain
the high prevalence of GDM. Differences in screening pro-
grams and diagnostic criteria are the main factors which
make it difficult to compare frequencies of GDM among
various populations [2,3]. It would have been more cor-
rect to compare our prevalence of GDM with that of
another Italian region which used the same screening
methods, however no such study has been published so
far. Nevertheless, although not conclusive, a number of
considerations can be made as a result. The extended
screening procedure we performed, namely a lower glyc-
emic threshold and three tests performed throughout the
index pregnancy, can only partly explain the difference
which resulted between other countries and other Italians
regions [29-33]. It is well known that lowering the thresh-
old of the OGCT increases sensitivity, at the expense of a
slightly lower specificity of the test. By using a lowered
threshold of the OGCT, we were able to diagnose an addi-
tional 12% of our cases of GDM, similar to findings
reported by others [7,35,36], although the prevalence of
GDM in their populations ranged from 2 to 6.8%. Thus,
the use of a lower threshold does not fully explain such an
elevated prevalence. Another important consideration to
be made is that almost half our GDM cases were diag-
nosed at 30–32 weeks of gestation, which goes along with
the progressively increasing insulin resistance during
pregnancy [37,38]. Therefore, it is possible that other
studies, where screening was performed at 24–28 weeks,
may have missed a significant number of the cases of
GDM. On the other hand, analyzing only the diagnoses
made through early and mid-pregnancy screening, our
prevalence is still surprisingly high (12%).
Our study showed that the "average risk" definition,
which characterized the majority of our patients, does not
identify patients at risk of GDM. This also excludes the
possibility of a selection bias to invalidate our results (that
is, too many "at risk" patients). On the contrary, despite
Table 2: Comparison between characteristics and risk factors in GDM and non-GDM patients
GDM
N = 247
Non-GDM
N= 856
P value
High risk [N, (%)] 98 (39.8) 133 (15) < 0.001
Average risk [N, (%)] 143 (57.8) 658 (76.8) < 0.001
Low risk [N, (%)] 5 (2.0) 66 (7.7) < 0.01
Age (mean ± SE) 32.8 ± 0.2 30.5 ± 0.1 < 0.001
Age < 25 [N, (%)] 7 (2.8) 110 (12.8) < 0.001
Age 25–34 [N, (%)] 145 (58.7) 554 (64.7) NS
Age ≥ 35 [N, (%)] 95 (38.4) 193 (22.5) < 0.01
BMI (media ± SE) 23.7 ± 0.2 22.1 ± 0.1 < 0.01
Obesity [N, (%)] 28 (11.3) 26 (3.0) < 0.001
Overweight [N, (%)] 46 (18.6) 114 (13,3) < 0.05
Type 2 diabetes in 1st-degree relative(s) [N, (%)] 65 (26.4) 92 (10.7) < 0.001
Type 2 diabetes in 2nd-degree relative(s) [N, (%)] 46 (18.6) 158 (18.4) NS
Prior GDM [N, (%)] 27 (10.9) 24 (2.8) < 0.001
Prior poor obstetrical outcomes [N, (%)] 91 (10.6) 43 (17.5) < 0.001
P = NS, Not Significant.
Table 3: Risk factors association with GDM
OR CI
Obesity (BMI ≥ 30 kg/m2) 3.7 2.08–6.8
Overweight (25 < BMI < 30 kg/m2) 1.4 1.00–2.21
Prior GDM 3.1 1.69–5.69
T2DM in 1st-degree relative(s) 2.6 1.81–3.86
Age, years 1.08 1.05–1.12
OR, Odds Ratio; CI, Confidence IntervalReproductive Biology and Endocrinology 2008, 6:26 http://www.rbej.com/content/6/1/26
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the low sensitivity of the high-risk definition, the high
odd ratio and good specificity seem to appropriately char-
acterize the population really "at risk" of GDM. Similarly,
the low risk definition identifies women who are unlikely
to develop GDM.
The analysis of the individual prevalences of risk factors
does not seem to show an unusual prevalence of any of
the risk factors sufficient to justify the high prevalence of
GDM. We compared our results from the general obstetric
population with those reported in other populations
[3,9,17,30,39]: in another Italian region, in the USA and
in northern and southern Europe (Table 5).
The analysis is rendered difficult by the often different def-
initions of the individual factors, for example obesity,
over-weight or poor obstetrical outcome, and in many
cases a comparison with our study was not possible.
Obesity is a well known risk factor for GDM, which is
strongly associated with GDM in our patients (OR: 3.7),
but it was present in only 4.9% of our overall population,
similarly to what has been found elsewhere in Italy [30]
and Spain [3], but considerably lower than the prevalence
reported (7.9%) in Sweden [39], and probably in the USA,
where 22% of patients have been reported to have a BMI
> 27. By contrast, in both the USA and Sweden, GDM
prevalence is very low. Thus, it seems unlikely that the
high prevalence of GDM in our population can be
explained by our prevalence of obesity.
The prevalence of prior GDM is higher to that reported in
other countries. This prevalence is obviously influenced
by the different proportion of primiparas and multiparas
in patient groups, not evaluated in our study. The Swedish
study [39] reported a percent of 1.3% in primiparas and
2.3% in multiparas, which is half the prior GDM in our
patients. Thus, it seems more likely that the prevalence of
prior GDM in our patients is linked to our GDM preva-
lence.
The results on family history vary considerably in the
studies evaluated, since the prevalence in our population
is similar only to that reported in Spain, lower to that
reported elsewhere in Italy and higher to that reported in
the USA and Sweden. However, several factors can influ-
ence this parameter. Firstly, none of the studies examined
specify whether the familiarity evaluated was for Type 1 or
Type 2 diabetes. Furthermore, it can be difficult to obtain
an accurate medical family history, especially in patients
from lower social status groups. This factor is also influ-
enced by age because if the patient is young Type 2 diabe-
Table 4: Validation of risk assessment strategy
OR 95% CI Sensitivity Specificity PPV NPV
High Risk 3.6 2.6–4.9 39.8% 84.5% 42.4% 83.4%
Average Risk 0.4 0.09–0.6 58% 23% 17.9% 66.9%
Low Risk 0.2 0.3–0.5 2% 92% 7% 77%
OR, Odds Ratio; CI, Confidence Interval; PPV, Positive Predictive Value; NPV, Negative Predictive Value
Table 5: Comparison of GDM and risk factors prevalence with other studies
Present study
Sardinia, Italy
Di Cianni 
Tuscany, Italy (30)
Danilenko-Dixon 
USA (9)
Jimenez-Moleon, 
Spain (3)
Ostlund, 
Sweden (40)
GDM prevalence 22.3% 8.74% 3% 2.5% 1.7%
Obesity (BMI ≥ 30 kg/m2) 4.9% 4.7% NA* 5.2% 7.9%
Overweight (25 < BMI < 30 kg/m2) 14.5% 12.6% NA NA§ NA ##
Prior GDM 4.6% NA 2.1% 0.8% 1.3%
T2DM in 1st-degree relative(s) 14.2% 18.1% ** 7.7%** 14.8%** 9.4%**
Age ≥ 25 yrs 89.3% NA 82.2% 80.3% 73.6
Prior poor obstetrical outcomes 12.1% NA NA*** NA # NA§§
NA = Not available
* In this study normal body weight is defined as BMI of < 27 kg/m2. The  percent of women with BMI > 25 was 33%, and the one of BMI > 27% was 
22%.
§ In this study patients with BMI 27–30 (7.1%) were evaluated
## In this study BMI ≥ 25 (28.3%) and ≥ 28 (12.3%) were evaluated
** In this study it is not specified if familiarity is for Type 1 or Type 2 diabetes
***In this study only prior macrosomia (14.5%) and prior foetal death (0.5%) were evaluated
# In this study prior macrosomia (4.9%), prior fetal death (1%), and congenital malformation were evaluated. The latter were not evaluated in our 
study (0.4%), whereas repeated abortions have not been reported.
§§ In this study only prior macrosomia was evaluatedReproductive Biology and Endocrinology 2008, 6:26 http://www.rbej.com/content/6/1/26
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tes is not yet detectable in parents. Thus, although in
absolute terms the prevalence of this factor in our general
population does not seem elevated, nothing can be con-
cluded from a comparison with other countries.
Although age is the most common risk factor, the percent-
age of women over 25 (89%), was only slightly higher
than that reported in the others studies, ranging from
82.2% in the USA [9] to 73.6% in Sweden [39] and is
association with GDM, though significant, is weak
(OR:1.08). Furthermore, only women over 34 (35 yrs or
more) were more represented in our GDM group. This
could mean that, at least in our population, age is a risk
factor only if women are over 34. This group of women is
26% of the overall population, very close to the 24.6%
reported in other Italian regions with a lower GDM prev-
alence [30]. Hence, the older age of our patients does not
seem sufficient to explain such a high GDM prevalence.
Furthermore, none of the studies which were compared
with our findings had examined prior obstetrical out-
comes, thus a comparison between prevalences was
impossible. However, this factor did not show a signifi-
cant association with GDM in our population, in agree-
ment with the findings of Kautzky-Willer [17], where the
same parameters as ours were evaluated (macrosomia,
polydramnios, repeated abortions, fetal death).
Conclusion
Such a high prevalence of GDM in our population does
not seem to be related to the abnormal presence of some
known risk factors, and appears in contrast with the prev-
alence of Type 2 diabetes.
Since Sardinia is a privileged territory with a very peculiar
genetic subset, which links Type 1 diabetes and other
autoimmune diseases to this Island, further studies to
examine the genetic and immunological pool of Sardin-
ian women of childbearing potential are needed.
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